Hanall Biopharma’s new immuno-oncology antibody drug, selected as a national new drug development project

Ahn Hye-kyung, head of Hanall Biopharma (center), has a meeting with researchers.[사진=한올바이오파마 제공]
Hanall Biopharma announced on the 4th that ‘HL187’, a new anti-cancer antibody drug, was selected as a project support project for the ‘New Drug R&D Ecosystem Construction Research’ by the National New Drug Development Project.

HL187 is an immune checkpoint inhibitor that has been jointly developed by Hanall Biopharma and Daewoong Pharmaceutical since 2016. It is a new antibody drug that targets the TIGIT protein, which controls the immune response in T cells or NK cells, and removes cancer cells by further enhancing immune cells by strengthening the function of the antibody Fc region.

HL187 demonstrated superior anticancer effects compared to competing substances in animal experiments conducted through overseas clinical contract organizations (CROs). In September, it signed a contract development and manufacturing (CDMO) contract with Samsung Biologics to receive services throughout production and development, and this government support is expected to accelerate the development of new drugs.

Ahn Hye-kyung, head of Hanall Biopharmaceutical Research Institute, said, “This selection of a national new drug development project is a great help in developing the next-generation immuno-oncology antibody based on Hanol’s human antibody technology and R&D capabilities confirmed through the ‘HL161 Autoimmune Disease Antibody Drug’. “We will further speed up the development of HL187 so that we can quickly launch a product that can become the hope of patients.”

Reporter Lee Ji-won [email protected]

Copyrightⓒ ‘Honest knowledge for health’ Comedy.com (http://kormedi.com) / Unauthorized reproduction-redistribution prohibited

Source: 코메디닷컴 by kormedi.com.

*The article has been translated based on the content of 코메디닷컴 by kormedi.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!